ClariVein(TM) Catheter For Varicose Veins: Further Clinical Trial Results To Be Presented

Main Category: Vascular
Also Included In: Clinical Trials / Drug Trials
Article Date: 19 Sep 2009 - 1:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Further results from the initial clinical trial of the ClariVein(TM) catheter, used in a new minimally invasive treatment for varicose veins, will be delivered on Friday, September 25, at the 23rd Annual Meeting of the Eastern Vascular Society in Philadelphia. The device combines mechanical and chemical modalities to accomplish vein treatment in an in-office setting.

Speaking is Steve Elias MD FACS FACPh, Associate Professor of Surgery at Mount Sinai Hospital, NY and the Director of The Centers for Vein Disease at Mount Sinai and Englewood Hospitals. Dr. Elias is the principle investigator of the trial, which was conducted at Englewood Hospital and Medical Center, NJ. Thirty patients were studied in this IRB-regulated trial.

"Initial results were very encouraging, and the success rates continue to be excellent as we follow patients over a longer period," Dr. Elias states. "The success rates are equal to the early results of radiofrequency or laser treatment of great saphenous vein disease. The main advantage is that the technique does not require tumescence anesthesia infusion, thus saving significant time and decreasing patient discomfort. In addition, no generator is required and capital and maintenance cost is reduced. This in-office procedure takes about 15 minutes to perform and patients resume normal activity that day. All patients would recommend the procedure to others."

The ClariVein(TM) catheter is a product of Vascular Insights LLC of Madison, CT. The company engages in the design, development, manufacture, and marketing of medical devices for the minimally invasive treatment of peripheral vascular disease. The company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market ClariVein(TM) for infusion of physician-specified agents in the peripheral vasculature.

Dr. Elias is scheduled to speak at the 10:00 am scientific session at the Loews Philadelphia Hotel.

Source: Vascular Insights LLC